Skip to content
Medical Health Aged Care

Join us today for the Gold Coast Memory Walk & Jog!

Dementia Australia 2 mins read

What: Dementia Australia’s Gold Coast Memory Walk & Jog  

  

When: Sunday, 1 June from 7:30am

  

Who: More than 1,000 locals participating on the day. People who have been impacted by dementia, their family, friends and carers. Special guests Takaya Honda.

  

Where: Pratten Park, Broadbeach

Dementia Australia spokespeople and local residents are available for interview.

 

Photos and video of previous Memory Walk & Jog events for publication are available for use.

 

For more information visit: https://www.memorywalk.com.au/event/gold-coast/home

 

Dementia Australia is the source of trusted information, education and services for the estimated more than 433,300 Australians living with dementia, and the more than 1.7 million people involved in their care. We advocate for positive change and support vital research. We are here to support people impacted by dementia, and to enable them to live as well as possible. No matter how you are impacted by dementia or who you are, we are here for you.

For support, please contact the National Dementia Helpline on 1800 100 500. An interpreter service is available. The National Dementia Helpline is funded by the Australian Government. People looking for information can also visit dementia.org.au

-Ends-

 

Media contacts: Teresa Cong, Senior Media & Communications Advisor, [email protected], 0423 383 564

When talking or writing about dementia please refer to Dementia-Friendly Language Guidelines.

Note to Editors:

Photos and video of previous Memory Walk & Jog events for publication are available for use.

We request, where possible, details for the National Dementia Helpline 1800 100 500 appear alongside news stories about dementia, as these stories often prompt questions or concerns:

If this story has prompted any questions or concerns, please call the National Dementia Helpline 1800 100 500 (24 hours, 7 days a week) or visit dementia.org.au.

Media

More from this category

  • Government Federal, Medical Health Aged Care
  • 25/06/2025
  • 00:05
ACSQHC

Spirometry in decline: a vital test for COPD left behind

25 June 2025 Australians living with chronic obstructive pulmonary disease (COPD) are being exposed to greater health risks as the use of a critical diagnostic test has fallen dramatically, according to a new national report released today by the Australian Commission on Safety and Quality in Health Care. The Atlas Focus Report: COPD found a 31% drop in spirometry testing rates between 2015-16 and 2022-23, despite the test being the gold standard for confirming a diagnosis of COPD. Without spirometry, patients are in danger of misdiagnosis and being prescribed medications that put them at unnecessary risk. COPD is a progressive,…

  • Contains:
  • Medical Health Aged Care
  • 24/06/2025
  • 23:26
Zepp Health

Amazfit Introduces Balance 2 Smartwatch and Helio Strap for Smarter Training, Better Recovery and Peak Performance

Amazfit Smart Wearables Require No Additional Subscription MILPITAS, Calif.–BUSINESS WIRE– Amazfit, a leading global smart wearable brand owned by Zepp Health (NYSE: ZEPP), a…

  • Contains:
  • Medical Health Aged Care
  • 24/06/2025
  • 21:10
Fortrea Holdings Inc

Fortrea & Emery Pharma Announce Strategic Collaboration to Deliver FDA Compliant Drug-Drug-Interaction Studies Using Rifampin

Collaboration enables testing of nitrosamine impurities, allowing sponsors to demonstrate acceptable use of rifampin in drug-drug interaction studiesDURHAM, N.C., June 24, 2025 (GLOBE NEWSWIRE) -- Fortrea (Nasdaq: FTRE) (the “Company”), a leading global contract research organization (CRO), today announced a strategic collaboration with Emery Pharma, a leading analytical and bioanalytical CRO providing testing services under current Good Manufacturing Practice (cGMP) and Good Laboratory Practice (GLP), to provide rapid lot-by-lot, 1-methyl-4-nitrosopiperazine (MNP) testing of rifampin, the preferred drug for drug-drug interaction (DDI) studies, to certify impurities are below the Acceptable Intake (AI) Limit set by U.S. Food and Drug Administration (FDA)…

Media Outreach made fast, easy, simple.

Feature your press release on Medianet's News Hub every time you distribute with Medianet. Pay per release or save with a subscription.